摘要
目的评价小剂量普通干扰素联合利巴韦林治疗失代偿期丙型肝炎肝硬化的疗效和安全性。方法 43例失代偿期丙型肝炎肝硬化患者使用α-2b干扰素联合利巴韦林抗病毒,采用从小剂量开始逐渐加量方案(LADR)治疗。α-2b干扰素初始剂量为200万U/次,皮下注射,每周3次,加利巴韦林600mg/d,分3次口服.治疗4周后,根据病情逐步将α-2b干扰素剂量增加至300万U/次皮下注射及利巴韦林900～1 200mg/d,分3次口服,疗程48周,停药后继续观察24周。结果 43例丙型肝炎肝硬化患者有39例耐受尚好并完成48周全疗程,治疗结束时病毒学应答为65.0%,持续病毒学应答为79.5%,生化指标、Child-Pugh评分明显改善。结论失代偿期丙型肝炎肝硬化采用LADR方案抗病毒治疗是安全有效的,但远期疗效有待进一步观察。
Objective To assess the efficacy and safety of low-dose interferon in combination with ribavirinin the treatment of hepatitis C in patients with decompensated cirrhosis. Methods 43 patients with decompensated liver cirrhosisdue to hepatitis C treated with interferonα-2b. The initial dose was 2 million U, three times a week, plus ribavirin 600mg/d, after the treatment 4 weeks, according to the disease gradually increased doses of interferon α-2b and ribavirin to 3 million U, 900-1200mg/d, the treatment for 48 weeks to observe the effect. Results 39 patients completed the interferonα- 2b treatment among 43 patients. Compared with prior treatment,the loads of HCV RNA, the indexes of liver function（ALT,AST,TBil, ALB） and Child-Pugh score were significantly improved after reatment （P 〈0.01）. Conclusions The low accelerating-dose regimen of interferonα-2b plus ribavirin is an optional strategy for the treatment deeompensated hepatitis C cirrhosis, but long term efficacy of treatment remains to be observed.
出处
《齐齐哈尔医学院学报》
2012年第9期1131-1132,共2页
Journal of Qiqihar Medical University
